UK-based biotechnology firm RQ Bio has successfully closed an oversubscribed Series A financing round, securing $115 million to advance its innovative antibody therapies. The funding was led by Frazier Life Sciences and attracted a syndicate of new and existing investors. This capital injection will primarily support the clinical development of the company's lead program, which aims to prevent seasonal influenza in high-risk and immunocompromised individuals.
A Novel Approach to Influenza Prevention
RQ Bio is focused on developing long-acting monoclonal antibodies that provide season-long protection against influenza from a single administration. This approach addresses a critical unmet need for vulnerable patients whose immune systems do not respond adequately to traditional vaccines. The company's vision is to establish a new standard of care for influenza prophylaxis in these at-risk populations.
The company's lead candidate, RQB01, is currently in IND-enabling studies and is designed to offer broad protection against diverse flu strains. It employs a differentiated dual mechanism of action that targets conserved epitopes, which are parts of the virus less susceptible to seasonal variation. This innovative design is intended to deliver potent neutralizing activity and an extended duration of action for reliable seasonal defense.
Strategic Investment and Investor Confidence
The substantial financing round highlights strong investor confidence in RQ Bio's scientific platform and strategic direction. The syndicate includes new investors EQT Life Sciences, Forbion, Monograph, and Wellington Management. They join founding investors LifeArc Ventures, Oxford Science Enterprises, and the University of Oxford, who also participated in the round.
Investor representatives have expressed enthusiasm for the company's potential to transform influenza prevention. Joe Cabral, Partner at Frazier Life Sciences, noted the therapy's differentiated attributes and will join the RQ Bio Board of Directors. This collective support will be instrumental as the company scales its operations and advances its pipeline of therapies for other infectious diseases.
Strengthening Leadership for Future Growth
In conjunction with the financing, RQ Bio has appointed biotechnology industry veteran Christian S. Schade as its new Executive Chairman. Schade brings significant leadership and transaction experience from numerous CEO and board roles across the sector. His appointment is a strategic move designed to guide the company's corporate strategy and support its continued growth.
Schade most recently served as President and CEO of Halda Therapeutics, which was acquired by Johnson & Johnson in 2025. In his new capacity, he will work closely with the management team and board to navigate the company's expansion. This addition fortifies the leadership team as RQ Bio prepares to transition its lead program into clinical trials.
With $115 million in new funding, a promising lead candidate, and strengthened leadership, RQ Bio is well-positioned to advance its mission. The company is now poised to enter a critical phase of clinical development, moving one step closer to delivering a new preventative option for vulnerable populations. This milestone represents a significant development in the ongoing effort to combat the persistent threat of seasonal influenza.